Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74

Affiliations

¹ Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
² Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address: chenminfeng1999@163.com.

Comment

Zhenyu Yang et al. Eur Urol. 2017 Jan.

. 2017 Jan;71(1):e23-e24.

doi: 10.1016/j.eururo.2016.06.016. Epub 2016 Jun 22.

¹ Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
² Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address: chenminfeng1999@163.com.

No abstract available

Comment on

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Tannir NM, et al. Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26. Eur Urol. 2016. PMID: 26626617 Free PMC article. Clinical Trial.